Clicky

Co-Diagnostics, Inc.(CODX)

Description: Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.


Keywords: Medicine Biotechnology Clinical Medicine Disease Acid Organisms Medical Test Diagnostic Tests Hepatitis B Molecular Diagnostics Tuberculosis Polymerase Chain Reaction Genetic Diseases Immunodeficiency Malaria Diagnostic Equipment Ortho Clinical Diagnostics Dengue Dengue Fever Zika Mdx

Home Page: www.codiagnostics.com

CODX Technical Analysis

2401 South Foothill Drive
Salt Lake City, UT 84109
United States
Phone: 801 438 1036


Officers

Name Title
Mr. Dwight H. Egan Chairman, CEO & Pres
Mr. Brian L. Brown CPA CFO & Company Sec.
Mr. Reed L. Benson Gen. Counsel
Dr. Brent C. Satterfield Ph.D. Co-Founder & Member of Scientific Advisory Board
Mr. Dan Bohrer CPA VP of Fin. & Accounting
Dr. Mark Poritz Ph.D. Chief Scientific Officer
Mr. Andrew Benson Head of Investor Relations
Dr. Mayuranki Almaula Sr. VP of Overseas Operations & Strategic Alliances
Mr. Cameron Gundry Head of Commercialization LATAM/EUR

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 16
Trailing PE: 5.0385
Price-to-Book MRQ: 0.6346
Price-to-Sales TTM: 1.4524
IPO Date: 2017-07-12
Fiscal Year End: December
Full Time Employees: 101
Back to stocks